Expert dialogue reviews the physiological discovery and clinical evolution of GLP-1 receptor agonists, highlighting their transformative potential across metabolic disease and public health.
The origins of glucagon-like peptide-1s (GLP-1s) and what comes next are discussed by JAMA Senior Editor Derek C. Angus, MD, MPH, and Jens Juul Holst, MD, DMSc, a professor of medical physiology at the University of Copenhagen, and Lotte Bjerre Knudsen, DMSc, professor, for the Healthy Dialogue podcast.
No takes yet. Share an insight, caveat, or question.
Angus et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: